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The difficulty of eliminating herpesvirus carriage makes host entry a key target for infection control.
However, its viral requirements are poorly defined. Murid herpesvirus-4 (MuHV-4) can potentially
provide insights into gammaherpesvirus host entry. Upper respiratory tract infection requires the
MuHV-4 thymidine kinase (TK) and ribonucleotide reductase large subunit (RNR-L), suggesting a
need for increased nucleotide production. However, both TK and RNR-L are likely to be
multifunctional. We therefore tested further the importance of nucleotide production by disrupting
the MuHV-4 ribonucleotide reductase small subunit (RNR-S). This caused a similar attenuation to
RNR-L disruption: despite reduced intra-host spread, invasive inoculations still established
infection, whereas a non-invasive upper respiratory tract inoculation did so only at high dose.
Histological analysis showed that RNR-S
”, RNR-L
” and TK
” viruses all infected cells in the
olfactory neuroepithelium but unlike wild-type virus then failed to spread. Thus captured host
nucleotide metabolism enzymes, up to now defined mainly as important for alphaherpesvirus
reactivation in neurons, also have a key role in gammaherpesvirus host entry. This seemed to
reflect a requirement for lytic replication to occur in a terminally differentiated cell before a viable
pool of latent genomes could be established.
INTRODUCTION
Herpesviruses have captured mutiple enzymes of host
nucleoside metabolism. Examples include thymidine kinase
(TK), which catalyses a rate-limiting step in dTTP
synthesis, and ribonucleotide reductase (RNR), which
makes dATP, dGTP and dCTP from the corresponding
ribonucleotides (Jordan & Reichard, 1998). Like the
cellular RNR, viral RNRs have a large catalytic subunit
(RNR-L) and a smaller one that supplies free radicals
(RNR-S). Both are essential for RNR activity (Ator et al.,
1986; Conner et al., 1994). The relative ease of adminis-
tering nucleoside analogues makes these enzymes prime
targets for antiviral chemotherapy (Cameron et al., 1988;
Wnuk & Robins, 2006). However, effective therapy also
requires that virus mutants lacking the target enzyme are
avirulent. Thus, while the ubiquity of captured enzymes in
alpha- and gamma-herpesvirus genomes implies one or
more important roles in host colonization, it is important
to understand more precisely what these roles might be.
Alphaherpesviruses require TK (Efstathiou et al., 1989;
Coen et al., 1989) and RNR (Jacobson et al., 1989; Yamada
et al., 1991) to reactivate from latency in neurons. The
consequent avirulence of TK
2 mutants allows acyclovir to
be a potent therapy against herpes simplex virus (HSV)
(Darby, 1993). Gammaherpesviruses by contrast are latent
in replication-competent lymphocytes, and appear not to
require TK or RNR for reactivation (Coleman et al., 2003;
Gill et al., 2010). Gammaherpesviruses also rarely present
before a self-renewing pool of infected lymphocytes is
established (Hoagland, 1964). Thus, acyclovir treatment
has had little effect on Epstein–Barr virus (EBV) latent
loads (Yao et al., 1989; Hoshino et al., 2009). However,
lytic replication may play a greater role in maintaining
latent loads and driving disease for rhadinoviruses
(gamma-2-herpesviruses) such as the Kaposi’s sarcoma-
associated herpesvirus (KSHV) (Ganem, 2006). Since the
narrow species tropism of KSHV largely precludes in vivo
studies, the related murid herpesvirus-4 (MuHV-4, arche-
typal strain MHV-68) (Stevenson et al., 2009) provides
a useful way to analyse conserved rhadinovirus gene
functions. TK
2 and RNR-L
2 MuHV-4 mutants establish
latency after intraperitoneal inoculation, but fail to
establish significant infections via the more likely natural
entry route of the upper respiratory tract (Gill et al., 2009,
2010). Specifically, they show no luciferase signals in the
upper respiratory tract after intranasal inoculation, and if
inoculation is confined to the upper respiratory tract then
infection remains detectable by PCR of spleen cells for viral
DNA and serum ELISA for virus-specific IgG. Therefore,
it seems that MuHV-4 must normally replicate in a
terminally differentiated cell to reach its latent reservoir.
This conclusion has important implications for KSHV and
EBV: despite salivary transmission being well established
(Faulkner et al., 2000; Pica & Volpi, 2007), how new hosts
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host genes can evolve new functions. Gammaherpesvirus
TKs are weak nucleoside kinases with large N-terminal
extensions that appear to be redundant for TK activity
(Gustafson et al., 1998), and the KSHV TK drives cell
rounding and detachment by an unknown mechanism
(Gill et al., 2005). Among other examples, the gamma-
herpesvirus ORF11 is a captured, non-functional dUTPase
(Davison & Stow, 2005), and MuHV-4 FGARAT homo-
logues have evolved important functions independent of
detectable FGARAT activity (Gaspar et al., 2008). Many
nucleoside metabolism enzymes captured by cytomegalo-
viruses have lost catalytic activity, including the murine
cytomegalovirus RNR-L, which has become an inhibitor of
inflammation (Brune et al., 2001; Upton et al., 2010). Like
human cytomegalovirus, murine cytomegalovirus also
appears to have lost its homologues of TK and RNR-S
(Rawlinson et al., 1996). The HSV-1 RNR-L inhibits
apoptosis (Langelier et al., 2002) even though it is still part
of a functional RNR. Therefore, MuHV-4 host entry via the
upper respiratory tract could require TK and RNR-L
functions unrelated to viral DNA replication. To test
further whether viral nucleoside metabolism enzymes are
required for this key aspect of the viral life cycle, we
analysed the phenotype of MuHV-4 lacking RNR-S.
Cellular RNR activity is thought to be limited mainly by
the availability of RNR-S (Jordan & Reichard, 1998). Non-
dividing cells can produce an alternative RNR-S (p53R2)
with possible roles in mitochondrial DNA replication and
DNA repair, but quiescent RNR activity is only 2–3% of
that in S phase. Whether the cellular RNR-L, RNR-S or
RNR-p53R2 can substitute for the corresponding viral
subunits is unclear. In vitro screens of random MuHV-4
mutants found an RNR-S mutant to be either more
attenuated than an RNR-L mutant (Song et al., 2005) or
equally attenuated (Moorman et al., 2004). Here, we show
that the MuHV-4 RNR-L has a striking perinuclear
distribution independent of RNR-S, suggesting additional
functions, but that MuHV-4 lacking RNR-S has a similar
phenotype to that lacking RNR-L, being unable to establish
a significant infection via the upper respiratory tract except
at high dose. Histological examination showed individual
infected cells in the olfactory neuroepithelium without
RNR-S, RNR-L or TK, but no subsequent viral spread.
Therefore, it appeared that MuHV-4 cannot move beyond
its primary target of the olfactory neuroepithelium without
supplementing cellular deoxyribonucleotide synthesis.
RESULTS
Generation of MuHV-4 lacking RNR-S
We generated two RNR-S mutants. In each, ORF60 was
disrupted after amino acid residue 72. One mutant had a
frameshift at this site (RNR-S
2FS); the other had an
additional deletion of the downstream 471 bp (RNR-
S
2DEL). Each was made on both a wild-type (WT) and a
luciferase-expressing virus background. We also generated
a revertant of the RNR-S
2FS mutation. A Southern blot of
viral DNA (Fig. 1) confirmed that each mutant contained
the expected genomic change.
Analysis of RNR subunit expression
The cellular RNR subunits have a diffuse cytoplasmic
distribution, based on the transfection of tagged expression
constructs (Pontarin et al., 2008). We transfected tagged
forms of the MuHV-4 RNR-S and RNR-L to establish their
distribution in a comparable manner (Fig. 2a). RNR-L
alone localized to linear structures around the nucleus.
RNR-S alone was diffusely cytoplasmic. In co-transfected
cells, RNR-L and RNR-S co-localized in the linear struc-
tures decorated by RNR-L. Therefore, RNR-L directed
RNR-S to structures not obviously associated with cellular
RNR expression. RNR-L and RNR-S also adopted peri-
nuclear localizations in MuHV-4-infected cells, with some
additional diffuse cytoplasmic staining of RNR-S (Fig. 2b).
Phosphonoacetic acid (PAA) treatment of the infected cells
Fig. 1. Genomic structure of MuHV-4 RNR-S mutants. (a)
Schematic diagram shows the RNR-S locus, between RNR-L
(ORF61) and ORF59, and the introduced DEL and FS mutations.
Each introduced a SacI restriction site. Also shown is the
luciferase expression cassette at genomic co-ordinate 77176,
which also introduces a SacI site. (b) Southern blot of WT, RNR-S
mutant (FS, DEL) and FS revertant (REV) viral DNA, digested with
SacI and probed for the RNR-S locus as shown in (a). A 18449 bp
band in the WT and revertant is digested to 14215+4234 bp in
the RNR-S
”FS mutant and to 14215+3764 bp in the RNR-
S
”DEL mutant. On the M3-LUC background the predicted bands
are 14215+5088 bp for RNR-S
”FS and 14215+4618 bp for
RNR-S
”DEL.
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products, like TK but unlike glycoprotein N (Fig. 2c).
Analysis of RNR-S and RNR-L mutants (Fig. 2d) confirmed
that each lacked the relevant viral gene product. The RNR-L
of RNR-S
2 MuHV-4 remained perinuclear, while the RNR-
S of RNR-L
2 MuHV-4 lost its perinuclear localization to
become just diffusely cytoplasmic. Therefore, the distribu-
tions of RNR-L and RNR-S in infected cells were consistent
with those observed in transfected cells.
RNR-S
” virus replication in vitro
RNR-S
2 virus mutants showed obvious attenuation in
vitro, with poor lytic propagation after BAC DNA
transfection into BHK-21 cells. Since plaque assays depend
on virus propagation for their readout, we also measured
virus titres by flow cytometry of human cytomegalovirus
immediate-early 1 promoter-driven viral eGFP expression
after overnight infection (eGFP U ml
21). As with RNR-L
2
mutants (Gill et al., 2010), the plaque titres of RNR-S
2
virus stocks were 10-fold lower than their eGFP titres,
whereas for RNR-S
+ viruses these titres were comparable
(data not shown). Therefore to determine the effect of
RNR-S disruption on in vitro virus growth, we used eGFP
+
viruses and calculated inputs and measured outputs by
eGFP units. RNR-S
2 mutants showed a moderate replica-
tion deficit (Fig. 3a), comparable to that of an RNR-L
2
mutant (Fig. 3b). The variation in RNR-S deficit between
Fig. 3(a) and Fig 3(b) reflects that MuHV-4 lytic
replication is far from uniform and can be highly
dependent upon parameters such as cell density. Thus
comparisons are only ever made within experiments, using
viruses titrated at the same time.
Fig. 2. Identification of the RNR-S and RNR-L gene products. (a) HeLa cells were transfected with tagged versions of RNR-S
and RNR-L, either singly or in combination. Fluorescence was examined 24 h later. RNR-L, green; RNR-S, red; co-localization,
yellow. Nuclei were counterstained with DAPI (blue). The cells shown are each representative of .100 examined. BHK-21 cells
were infected with WT MuHV-4 (1 p.f.u. per cell, 18 h), then fixed, permeabilized and stained for RNR-L or RNR-S with mAbs
as indicated. (c) BHK-21 cells were left uninfected or infected with WT MuHV-4 (0.5 eGFP U per cell, 18 h) with or without
100 mg PAA ml
”1 to block viral late gene expression. The cells were then fixed, permeabilized and stained for gN with mAb 3F7,
for RNR-L with mAb BZ-5B2, for RNR-S with mAb PS-10A10 and for TK with mAb CS-4A5 (red). Nuclei were counterstained
with DAPI (blue). (d) BHK-21 cells were infected with WT, RNR-L
”STOP or RNR-S
”FS MuHV-4 (eGFP U per cell, 18 h) then
stained for gN, RNR-L, RNR-S or TK as in (c) to show the effect on RNR subunit disruptions on the distribution of the remaining
subunit. Equivalent results were obtained with independently derived RNR-L and RNR-S mutants.
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” virus luciferase expression in vivo
We monitored host colonization first by luciferase
expression (Fig. 4), since the readout per cell by this
method is relatively independent of viral late gene
expression (Milho et al., 2009). After intranasal (i.n.) virus
inoculation under anaesthesia (Fig. 4a, b), WT luciferase
signals were visible in noses and lungs. RNR-S
2 luciferase
signals were also visible in lungs, albeit weaker than those
of the WT (Fig. 4a), and were not visible in noses (Fig. 4b).
After i.n. virus inoculation without anaesthesia (Fig. 4c),
WT luciferase signals were visible in noses, and after
12 days in the draining superficial cervical lymph nodes
(SCLN), whereas RNR-S
2 signals were absent from both
sites. After intraperitoneal (i.p.) virus inoculation, both
RNR-S
+ and RNR-S
2 peritoneal luciferase signals were
detected. Again the RNR-S
+ signal was greater, consistent
with RNR-S
2 mutants being attenuated for in vivo lytic
spread, but infection was clearly established (Fig. 4d).
Thus, it appeared that RNR-S
2 mutants could infect mice
via the lung or peritoneum but not via the nose.
Establishment and persistence of RNR-S
” viral
genomes in lymphoid tissue
Viral luciferase expression depends on a lytic cycle
promoter (Milho et al., 2009) that is likely to be shut
down during latency. Therefore, we assayed long-term
infection by quantitative PCR of viral DNA from spleens
3 months after exposure to RNR-S
+ or RNR-S
2 viruses
(Fig. 5a, b). RNR-S
2 genomes were detected in the spleens
of 7/12 mice after i.p. inoculation and 6/12 mice after
intra-lung inoculation (Fig. 5a). This assay has limited
sensitivity as it samples only a small fraction of the total
host DNA, and even WT genomes persist at low
abundance. Therefore even though RNR-S
2 viral genomes
were not always detected, it seemed that after invasive
inoculation RNR-S was not required to establish a
persistent infection. In contrast, RNR-S
2 genomes were
not detected in the spleens of any mice 2 months after
virus inoculation into the nose (Fig. 5b). Nor were splenic
infectious centres (Fig. 5c). Therefore, MuHV-4 required
RNR-S to reach the spleen via the upper respiratory tract.
Antibody response to RNR-S
” virus inoculation
To allow for the inherent difficulty of excluding host
colonization by a virus that spreads poorly, we also
measured MuHV-4-specific serum IgG (Fig. 5d, e). While
a positive antibody response would not establish virus
persistence, a negative response would argue strongly
against a significant infection having occurred. Both i.p.
and i.n. (lung) RNR-S
2 virus inoculations elicited readily
detectable antibody responses (Fig. 5d). Thus, ELISA
identified evidence of RNR-S
2 infection having occurred
even when PCR of splenic DNA (Fig. 5a) did not. In
contrast, only RNR-S
+ MuHV-4 elicited a detectable
antibody response after inoculation into the nose (Fig. 5e).
Therefore, RNR-S
2 MuHV-4 either failed to infect by this
route or remained at a very low level.
Infection by luc
”RNR-S
” MuHV-4
We also tested infection by luciferase
2 RNR-S
2 mutants,
using as readouts PCR of viral DNA and ELISA of virus-
specific serum IgG (Fig. 6). Mice were infected (10
4 p.f.u.)
either i.p. or in the upper respiratory tract and analysed
1 month later. As with the luciferase
+ infections, both viral
genomes and virus-specific antibodies were detected after
i.p. inoculation. However, 3/12 mice given i.n. RNR-S
2
virus also showed evidence of infection by PCR, and 5/12
did so by IgG ELISA. The fact that mice were infected here,
but not by luc
+RNR-S
2 MuHV-4 (Fig. 5), most likely
Fig. 3. Growth of RNR-S
” MuHV-4 in vitro. (a) BHK-21 cells were
infected with eGFP
+RNR-S
+ (WT, revertant) or eGFP
+RNR-S
”
(DEL, FS) viruses (0.01 eGFP U per cell) and then cultured at
37 6C. Replicate cultures were harvested every 24 h and assayed
for infectivity by overnight infection of fresh BHK-21 cells and then
assay of those cells for viral eGFP expression by flow cytometry.
(b) BHK-21 cells were infected (0.01 eGFP U per cell) with
eGFP
+ WT, RNR-S
” or RNR-L
” (RNR-L
”STOP) viruses. Cultures
were then assayed for virus replication by eGFP infectious units as
in (a).
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4 p.f.u. inoculum
versus 10
3 p.f.u.). We have observed a similar dose
dependence with i.n. TK
2 infection (Gill et al., 2009).
With lower doses of luc
2RNR-S
2 viruses, ELISAs showed
no virus-specific serum IgG (Fig. 6c).
Histological identification of RNR-S
” infection in
the nose
To understand better the fate of RNR-S
2 viruses delivered
to the nose, we examined this site by immunohistochem-
istry (Fig. 7). To avoid the problem of RNR-S deficiency
limiting expression of the viral late gene products that are
the predominant targets for immune sera, we used eGFP
+
viruses and identified infected cells at 1 and 3 days post-
inoculation by staining for eGFP. At 1 day post-inocu-
lation, WT infection was restricted to isolated cells of the
olfactory neuroepithelium. A similar pattern was observed
with the RNR-S
2FS mutant. At 3 days post-inoculation,
RNR-S
2FS infection was still restricted to isolated cells. In
contrast, the WT had spread to form clusters of infected
neuroepithelial cells. TK
2 and RNR-L
2 mutants appeared
similar to the RNR-S
2 mutant. Therefore MuHV-4 could
infect the olfactory neuroepithelium without RNR-S, RNR-
L or TK, but failed to spread. This explained the lack of
luciferase signals in noses, since WT infection is rarely
detectable in the nose by CCD camera scanning at 1 day
post-inoculation – some virus spread is required to exceed
the detection threshold. A lack of late viral lytic gene
expression or spread similarly explained the lack of a
detectable antibody response to RNR-S
2 virus in the upper
respiratory tract.
We occasionally observed infection of the nasal respiratory
epithelium. This was much less common than neuro-
epithelial infection. It possibly represented a low efficiency
infection route to explain the occasional host coloniza-
tion achieved by high dose RNR-S
2 virus inoculations
(Fig. 6).
Fig. 4. Host colonization by RNR-S
” MuHV-4, monitored by luciferase imaging. (a) Mice were inoculated i.n. with WT or RNR-
S- (FS, DEL) viruses (10
3 p.f.u.) in 30 ml under anaesthesia. Infection in different sites was then imaged by injection with luciferin
and CCD camera scanning. Each point shows the result for one mouse. WT signals were markedly higher than mutant virus
signals, but no mice remained luciferase-negative. (b) Only WT-infected mice gave positive signals in the noses of the same
mice. (c) Mice were inoculated i.n. with WT or RNR-S
”FS viruses (10
3 p.f.u.) in 5 ml without anaesthesia, then imaged for viral
luciferase expression as in (a). No luciferase signals were detected in the lungs. Only WT MuHV-4 gave detectable signals in
noses, or at day 12 post-inoculation in the SCLN. (d) Mice were inoculated i.p. with WT or RNR-S
” (FS, DEL) viruses (10
3
p.f.u.), then monitored for viral luciferase expression as in (a). All mice showed positive signals.
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Epidemiology can reveal likely modes of gammaherpesvirus
transmission, but rarely the primary cells that incoming
virions target or how infection then spreads. This is
important, because gammaherpesviruses may infect different
cell types in different ways (Hutt-Fletcher, 2007; Shannon-
Lowe et al., 2009), mandating different interventions for
infection control. Here, efficient host entry via the upper
respiratory tract required viral enzymes that function in
nucleotide supply. Each enzyme may also have evolved new
functions. However, the similar phenotypes of three separate
gene disruptions (TK, RNR-L and now RNR-S) would argue
that their common function of nucleotide supply is what
host entry requires. Histological analysis provided a plausible
explanation: MuHV-4 must infect and replicate lytically in
differentiated olfactory neuroepithelial cells in order to reach
the B-cells that provide its normal latent reservoir.
The different requirements for host entry between nose,
lung and peritoneal cavity argued that inoculation route is
an important consideration when extrapolating experi-
mental results to a more natural setting. Aerosolized, virus-
laden droplets can in theory reach the lung without
anaesthesia, but the distance to travel and possibilities for
capture en route are very great, implying that this would
require copious virus shedding, and there is no epidemio-
logical evidence for gammaherpesvirus transmission in this
way. Therefore, inoculating MuHV-4 into lungs must be
considered artificially invasive. MuHV-4 (10
4 p.f.u. of WT)
delivered i.n. in 5 ml never infects the lungs if given without
anaesthesia (Milho et al., 2009), and rarely infects the lungs
even if given under general anaesthesia (data not shown). A
rough scaling factor of 3000 would make 5 ml in a mouse
equivalent to 15 ml in a human – a considerably greater
volume than is likely to be involved in natural transmis-
sion. Upper respiratory tract infection, by contrast, works
even with a 1 ml inoculum. Thus while MuHV-4 DNA can
persist without lytic replication if it reaches a suitable site
(Tibbetts et al., 2006; Moser et al., 2006; Kayhan et al.,
2007), unless the normal barriers to host entry are bypassed
Fig. 5. Host colonization by RNR-S
” MuHV-4, monitored by PCR for viral DNA and ELISA for virus-specific serum IgG. (a) Mice
were infected i.p. or i.n. under anaesthesia (10
3 p.f.u.) and 3 months later analysed for viral genomes by quantitative PCR of
splenic DNA. Viral (M2) copy numbers were normalized by the cellular APRT copy number, amplified in parallel for each sample.
Each point shows the result for one mouse. The dashed lines show the detection limit ratio of 0.17, equivalent to five viral copies
per reaction. (b). The same analysis was applied to mice 2 months after MuHV-4 inoculation (10
3 p.f.u.) into just the upper
respiratory tract. (c) The mice in (b) were analysed for recoverable virus by infectious centre assay of splenocytes. Each point
shows the result for one mouse. The dashed line shows the limit of assay detection. (d) Sera from the mice in (a) were analysed
for MuHV-4-specific IgG by ELISA. All showed substantial responses compared with the naive control. Each line shows the
mean absorbance reading for three mice. (e) Sera from the mice in (b) were analysed for MuHV-4-specific IgG by ELISA. No
antibody response to RNR-S
” MuHV-4 was detected. Each line shows the result for one mouse.
MuHV-4 RNR in vivo
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may survive for some time in the olfactory neuroepithe-
lium, but seems not to colonize the nervous system after
intranasal inoculation (Terry et al., 2000), and so is
unlikely to persist in neurons or glial cells. We have found
it difficult to recover even WT MuHV-4 from the olfactory
neuroepithelium in the long term.
An olfactory entry route makes sense for a murid
herpesvirus, because it exploits normal host environmental
sampling to achieve efficient virion uptake. Human noses,
being further from the ground, might seem less suitable
targets. However, gammaherpesvirus–host relationships
were established long before humans evolved. Therefore
the general scheme of host entry proceeding via terminally
differentiated epithelial cells and so requiring viral nucleo-
tide metabolism enzymes seems likely to be conserved,
particularly between rhadinoviruses. (MuHV-4 and KSHV
are more closely related to each-other than either is to
EBV.) Although the main role defined for HSV nucleotide
metabolism enzymes is to reactivate from neurons rather
than to infect them in the first place, experimental HSV
delivery typically involves scarification; a less invasive
inoculation might give different results. We find that TK
+
but not TK
2 vaccinia virus elicits an antibody response
after upper respiratory tract inoculation, whereas both
elicit antibody responses after i.p. inoculation (data not
shown). Therefore many DNA viruses may encounter
terminally differentiated cells when they first enter new
hosts, and so need to boost cellular deoxyribonucleotide
production in order to spread.
A requirement for viral lytic replication to reach a viable
latent reservoir opens up the possibility of arresting
Fig. 6. Dose-dependent infection by RNR-S
” MuHV-4. (a) Mice were infected (10
4 p.f.u.) either i.p. or in the upper respiratory
tract (i.n.). Sera were tested 1 month later for MuHV-4-specific IgG. Each line shows the result for 1 of 6 mice per group. The
dashed line shows the lower detection limit, set by the age-matched naive sera. (b) The mice in (a) were analysed for viral
genome carriage by PCR of splenic DNA. Each point shows the result for one mouse, with the viral copy number (M2)
normalized according to the cellular DNA copy number (APRT) of the same sample. The dashed line shows the detection limit.
(c) The results of ELISAs for MuHV-4-specific serum IgG at 1 month post-inoculation are summarized for different inoculation
doses of RNR-S
+ and RNR-S
” viruses. The 10
4 p.f.u. result is that illustrated in (a).
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nucleoside analogues. However, such treatments would
have to be based on a suspicion of contact rather than
symptoms. Thus they would probably be restricted to
settings such as immunocompromised patients inadver-
tently exposed to primary infection. Also we do not know
how long the initial neuroepithelial infection remains
viable for further dissemination. Therefore considerable
hurdles remain. Nevertheless, the requirement for multiple
viral genes – RNR-S, RNR-L, TK and presumably also the
viral DNA polymerase – indicates that such treatments
would have a range of possible targets.
METHODS
Mice. Female BALB/c mice (6–12 weeks old) were infected i.n. with
MuHV-4 (10
3 p.f.u. unless stated otherwise), either in 30 ml under
general anaesthesia to infect both upper and lower respiratory tracts,
or in 5 ml without anaesthesia to infect just the upper respiratory
tract. I.p. infections were with 10
3 p.f.u. in 300 ml. To monitor viral
luciferase expression, mice were injected i.p. with luciferin (2 mg per
mouse) and scanned with an IVIS Lumina CCD camera (Caliper Life
Sciences) (Milho et al., 2009). Quantitative comparisons used the
maximum radiance (photons s
21 cm
22) over each region of interest.
All experiments conformed to local animal ethics regulations and to
Home Office Project Licence 80/1992.
Plasmids and viruses. The MuHV-4 RNR-S is encoded by ORF60
(genomic co-ordinates 80479–79562), and RNR-L by ORF61 (geno-
mic co-ordinates 82865–80514) (Virgin et al., 1997). Fluorescent
tagged RNR subunits were cloned by PCR amplification (Phusion
DNA polymerase; New England Biolabs) of ORF60 with EcoRI/
BamHI restricted primers and of ORF61 with XhoI/BamHI restricted
primers. ORF61 was cloned into the XhoI/BamHI sites of pEGFPC2
(Clontech), thereby adding eGFP to its N terminus. ORF60 was
cloned into the EcoRI/BamHI sites of a pEGFPC2 derivative in which
the mCherry coding sequence replaces that of eGFP, thereby fusing
mCherry to the ORF60 N terminus.
An RNR-L mutant has been described previously (Gill et al., 2010).
To make an ORF60-disrupted virus, we PCR-amplified genomic co-
ordinates 81534–80265, including BamHI and SacI restriction sites
in the primers (59-GAGGGATCCATTGAGAGGCTGGAGAGGG-39;
59-CAGGAGCTCGATGTTAAAGTTGACCAGCCTC-39), and cloned
the PCR product into the same sites of pSP73 (Promega Cor-
poration). We then amplified two alternative second flanks, from the
BglII restriction site at genomic co-ordinate 78718 (59-CATACA-
ATCAAAGATCTAATCAAAC-39) to either genomic co-ordinate
79793 (59-GGAGAGCTCCTTTATTGCTGCCAAGAGCAAGA-39)o r
80261 (59-TCGGAGCTCTGGTCAAGGAGTTTAATTGCCATG-39).
A SacI restriction site was included in each second primer, and the
PCR product was cloned into the SacI/BglII sites of pSP73. Thus the
two genomic flanks, separated by a SacI site, incorporated either a
frameshift in the RNR-S coding sequence after amino acid residue 72
(RNR-S
2FS), or a deletion of genomic co-ordinates 80264–79794
(RNR-S
2DEL). Each construct was subcloned as a BglII–BamHI
Fig. 7. Neuroepithelial infection by MuHV-4 lacking nucleotide metabolism enzymes. Mice were infected i.n. (10
5 p.f.u., 5 ml, no
anaesthesia) with eGFP
+ MuHV-4. At 1 or 3 days post-inoculation, noses were removed post-mortem, fixed and decalcified.
Sections (7 mm) were then stained for viral eGFP expression (brown), and counterstained with Mayer’s haemalum (blue). Each
section shows a representative area of olfactory neuroepithelium from one mouse. Three mice were analysed at each time point
and gave similar results. At 1 day post-inoculation, all viruses were limited to isolated neuroepithelial cells. By day 3 post-
inoculation, WT infection had spread, whereas RNR-S
”, RNR-L
” and TK
” mutants had not.
MuHV-4 RNR in vivo
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then recombined into a MuHV-4 BAC by transient RecA expression
(Adler et al., 2000). A revertant of the RNR-S-FS mutant BAC was
made by reconstituting the corresponding unmutated genomic frag-
ment. We also generated luciferase
+ RNR-S-FS and RNR-S-DEL
mutants by shuttling the same ORF60 disruptions into an MuHV-4
BAC in which luciferase is expressed from an ectopic viral lytic
promoter in the ORF57–ORF58 intergenic site (Milho et al., 2009).
Recombinant BACs were tested for genomic integrity by restriction
endonuclease mapping and by DNA sequencing across the mutation
site. Recombinant viruses were recovered by transfecting BAC DNA
into BHK-21 cells. For in vivo experiments, the loxP-flanked viral
BAC–eGFP cassette was removed by passage through NIH-3T3-CRE
cells (Stevenson et al., 2002). Virus stocks were grown in BHK-21 cells
and recovered from infected cell supernatants by ultracentrifugation
(de Lima et al., 2004).
Cells and mAbs. BHK-21 cells, HeLa cells and NIH-3T3-CRE cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen Corporation) supplemented with 2 mM glutamine, 100 U
penicillin ml
21, 100 mg streptomycin ml
21 and 10% FCS (PAA
Laboratories). Cells were transfected using either Fugene-6 (for BAC
DNA) or Lipofectamine (for expression plasmids). B-cell hybridomas
were generated by fusing splenocytes with NS0 cells. Hybrids were
cultured on irradiated MRC-5 feeder cells in RPMI 1640 supple-
mented as for DMEM, and selected with 1 mg azaserine ml
21 plus
100 mM hypoxanthine (Gillet et al., 2007). We isolated two IgG2a
mAbs specific for RNR-L (PS-8A7 and BZ-5B2) and one IgG2a mAb
specific for RNR-S (PS-10A10).
Virus assays. Virus stocks were titrated by plaque assay on BHK-21
cells (de Lima et al., 2004). Cell monolayers were incubated with virus
dilutions (2 h, 37 uC), overlaid with 0.3% carboxy-methylcellulose,
and 4 days later fixed and stained for plaque counting. Latent virus in
spleens was measured by infectious centre assay (de Lima et al., 2004).
Viral genome loads were measured by real-time PCR (Gaspar et al.,
2008). DNA (50 ng) was extracted from ex vivo organs (Wizard
genomic DNA purification kit; Promega Corporation) and used to
amplify MuHV-4 genomic co-ordinates 4166–4252 (M2 gene) (Rotor
Gene 3000; Corbett Research). The PCR products were quantified by
hybridization with a Taqman probe (genomic co-ordinates 4218–
4189) and converted to genome copies by comparison with a
standard curve of cloned plasmid template amplified in parallel.
Cellular DNA was quantified in the same reaction by amplifying part
of the adenosine phosphoribosyltransferase (APRT) gene (forward
primer 59-GGGGCAAAACCAAAAAAGGA-39, reverse primer 59-
TGTGTGTGGGGCCTGAGTC-39, probe 59-TGCCTAAACACAAGC-
ATCCCTACCTCAA-39), again with plasmid template dilutions
amplified in parallel for quantification. Virus loads were then
expressed relative to the cellular genome copy number of each sample.
ELISA. MuHV-4 virions recovered from infected cell supernatants
were disrupted with 0.05% Triton X-100 in 50 mM sodium
carbonate (pH 8.5), and coated (18 h, 4 uC) onto Maxisorp ELISA
plates (Nalge Nunc). The plates were washed three times in PBS/0.1%
Tween-20, blocked with 2% BSA in PBS/0.1% Tween-20 (1 h,
23 uC), and incubated with threefold serum dilutions (1 h, 23 uC).
The plates were then washed four times in PBS/0.1% Tween-20,
incubated (1 h, 23 uC) with alkaline phosphatase-conjugated goat
anti-mouse IgG-Fc pAb (Sigma Chemical Co.), washed five times,
and developed with nitrophenylphosphate. Absorbance was read at
405 nm with a Bio-Rad Benchmark ELISA plate reader.
Southern blotting. Virions were recovered from infected cell
supernatants by ultracentrifugation. DNA was extracted from them
by alkaline lysis, digested with EcoRI, electrophoresed on a 0.8%
agarose gel and transferred to positively charged nylon membranes
(Roche Diagnostics Ltd). A
32P-dCTP-labelled probe (APBiotech) was
generated by random primer extension (Nonaprimer kit; Qbiogene)
of a cloned ORF60 template. Membranes were hybridized with the
probe (65 uC, 18 h), washed to a stringency of 0.2% SSC, 0.1% SDS
and exposed to X-ray film.
Immunofluorescence. MuHV-4-infected BHK-21 cells or trans-
fected HeLa cells were fixed in 4% paraformaldehyde (30 min), then
washed in PBS and permeabilized with 0.1% Triton X-100. Viral
eGFP expression was visualized directly. Other viral proteins were
detected with MuHV-4-specific mAbs plus Alexa 568-coupled goat
anti-mouse IgG pAb (Invitrogen Corporation), washing the cells
three times with PBS/0.1% Tween-20 after each antibody incubation.
Nuclei were counterstained with DAPI. Fluorescence was visualized
by using a Leica confocal microscope or an Olympus fluorescence
microscope with digital image capture (Q Imaging).
Flow cytometry. Cells exposed to eGFP
+ viruses were trypsinized
and analysed for green channel fluorescence on a FACSort using
Cellquest (BD Biosciences).
Immunohistochemistry. The anterior part of the skull containing
the olfactory epithelium was removed post-mortem and fixed in 4%
formaldehyde–PBS (4 uC, 24 h). Samples were decalcified by gentle
agitation in 150 mM NaCl, 50 mM Tris/HCl (pH 7.2), 270 mM
EDTA (2 weeks, 23 uC), changing the buffer every 3 days, then
washed twice in PBS and paraffin-embedded. Sections (7 mm) were
de-paraffinized in xylene and rehydrated through graded ethanol
solutions. Antigen retrieval was performed by microwaving two times
for 5 min in 10 mM sodium citrate (pH 6), 0.05% Tween-20.
Endogenous peroxidase activity was quenched in PBS with 3% H2O2
for 10 min. Sections were blocked with the Avidin/Biotin Blocking kit
(Vector Laboratories) and in PBS with 2% goat serum, 2% BSA (1 h,
23 uC). Infected cells were detected with rabbit anti-eGFP pAb
(Abcam) (18 h, 23 uC). Subsequently, sections were incubated for
30 min in biotinylated goat anti-rabbit IgG pAb (Vector) and the
Vectastain Elite ABC Peroxidase system with ImmPACT DAB
substrate (Vector Laboratories). Sections were washed in PBS between
each step. Finally, the sections were counterstained with Mayer’s
Hemalum (Merck), dehydrated and mounted in DPX (BDH
Chemicals).
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